Conditions: Lymphoma, Non-Hodgkin
Keywords: Lymphoma, Non-Hodgkin, Low-Grade
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 12
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether the combination of bendamustine and bortezomib in patients with indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia is safe and tolerable.

Detailed description:
Bendamustin and bortezomib have been shown to be effective in the treatment of patients with indolent Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL). Both compounds appear not to be cross-resistant with prior therapy. Therefore, it is of interest to combine bendamustine and bortezomib in this patient population.

Preliminary results from patients with multiple myeloma showed that the combination of bendamustine and bortezomib is efficacious and well tolerated. However, there are so far no data on this combination in patients with NHL or CLL.

Arms:
arm 1: Combination Chemotherapy of Bendamustine and Bortezomib as described in the intervention section

Interventions: intervention 1: Bendamustine intervention 2: Bortezomib
Intervention descriptions: intervention 1: starting with 60 mg/m\^ 2, IV, dose escalation, weekly d1,8,15 q5w intervention 2: weekly 1.5mg/m\^2, IV, d1,8,15,22 q5w

Protocol document: